Key Points
- Guardant Health director Steve Krognes sold 6,674 shares at an average price of $175.74, totaling approximately $1.17 million. The sale reduced his position by 45.78%, leaving him with 7,906 shares.
- Guardant Health reported quarterly revenue of approximately $335 million, up 44.3% year over year and above estimates, while its adjusted loss of $0.42 per share was narrower than expected.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus rating and an average price target of $188.12, although the stock’s recent rally and additional insider sales may raise profit-taking concerns.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 116 shares of the business's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total value of $20,300.00. Following the completion of the sale, the director owned 11,449 shares of the company's stock, valued at $2,003,575. The trade was a 1.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Musa Tariq also recently made the following trade(s):
- On Monday, August 17th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $156.45, for a total value of $18,148.20.
- On Monday, June 22nd, Musa Tariq sold 1,951 shares of Guardant Health stock. The stock was sold at an average price of $131.16, for a total value of $255,893.16.
Guardant Health Trading Up 4.7%
Shares of Guardant Health stock opened at $183.10 on Friday. The firm has a market cap of $24.57 billion, a P/E ratio of -52.46 and a beta of 1.57. Guardant Health, Inc. has a 12 month low of $55.38 and a 12 month high of $183.51. The stock's fifty day moving average price is $160.71 and its 200-day moving average price is $127.10.
Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to analysts' expectations of $314.23 million. During the same period last year, the company earned ($0.44) earnings per share. The firm's revenue was up 44.3% compared to the same quarter last year. Analysts forecast that Guardant Health, Inc. will post -2.98 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages recently commented on GH. Canaccord Genuity Group boosted their price objective on shares of Guardant Health from $135.00 to $205.00 and gave the stock a "buy" rating in a research note on Tuesday, July 14th. Bank of America boosted their price target on Guardant Health from $135.00 to $190.00 and gave the stock a "buy" rating in a research report on Monday, July 6th. Citigroup raised their price objective on Guardant Health from $150.00 to $215.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. lifted their target price on Guardant Health from $185.00 to $195.00 and gave the company an "overweight" rating in a research note on Friday, July 31st. Finally, Morgan Stanley increased their price target on shares of Guardant Health from $175.00 to $185.00 and gave the company an "overweight" rating in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $188.12.
Read Our Latest Stock Report on Guardant Health
Institutional Trading of Guardant Health
Large investors have recently bought and sold shares of the stock. MCF Advisors LLC lifted its position in Guardant Health by 755.0% during the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company's stock worth $26,000 after acquiring an additional 151 shares during the period. Elyxium Wealth LLC acquired a new position in shares of Guardant Health in the fourth quarter valued at about $35,000. Ascentis Independent Advisors purchased a new position in shares of Guardant Health in the first quarter worth about $38,000. Hollencrest Capital Management acquired a new stake in shares of Guardant Health during the first quarter worth about $41,000. Finally, TrinityBridge Ltd acquired a new stake in shares of Guardant Health during the second quarter worth about $45,000. Hedge funds and other institutional investors own 92.60% of the company's stock.
Key Headlines Impacting Guardant Health
Here are the key news stories impacting Guardant Health this week:
- Positive Sentiment: Guardant Health was described as nearing a technical buy point as its sales outlook improves, reinforcing expectations for continued growth in its precision-oncology testing business. Guardant Health Nears Buy Point As Sales Outlook Brightens
- Positive Sentiment: Recent quarterly performance remains a key catalyst: revenue increased 44.3% year over year to about $335 million and exceeded analyst expectations, while the adjusted loss of $0.42 per share was narrower than the anticipated $0.76 loss. The results support the bullish sales narrative. Testing and diagnostics services stocks Q2 results
- Positive Sentiment: Wall Street sentiment is broadly favorable. Twenty-four analysts rate the stock Buy, one rates it Strong Buy and one rates it Sell; the average price target is approximately $188.12, with targets as high as $200. Guardant Health analyst ratings
- Neutral Sentiment: A comparison article examining Guardant Health and Joint did not identify a major new operating catalyst for GH, leaving the investment case centered primarily on growth, valuation and execution. Guardant Health and Joint comparison
- Negative Sentiment: Several insiders reported sales executed around $175-$178 per share. Director Steve Krognes sold 6,674 shares worth about $1.17 million, CTO Darya Chudova sold 7,738 shares worth about $1.38 million, and Director Alex Azar II sold 826 shares worth about $145,000. These transactions reduce insider ownership and may encourage profit-taking, although some were made under pre-arranged Rule 10b5-1 plans. Guardant Health insider sales
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.
The company's products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
